MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $65.07M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.09M
Average 0.04M
Returns on capital
MediciNova, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.9%
avg -21.8%
ROIC
-31.6%
avg -22.1%
ROA
-26.3%
avg -20.0%
Analysis
ROA is currently the strongest return metric at -26.3% versus its period average of -20.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Yuichi Iwaki | Co-Founder, President, Chief Executive Officer & Chairman | USD 1.01M | 76 | 450.00K | 0.91% |
Kazuko Matsuda | Senior VP, Chief Medical Officer & Director | USD 741.19K | 60 | 350.00K | 0.71% |
David H. Crean | Chief Business Officer | USD 120K | 61 | — | — |
Jason J. Kruger | Chief Financial Officer & Principal Financial Officer | — | 48 | 0 | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 16, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$1.73M
Net Transaction Value
−$1.73M
Net selling
Most Active
3D Investment Partners Pte. Ltd.
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 25, 26Sep 25, 2026 | 3D Investment Partners Pte. Ltd. Indirect | Sell | $1.7M$1,728,000.00 |
Summary
Insiders reported 0 buys worth $0.00 and 1 sells worth $1.73M over the last 12 months. That adds up to net selling of $1.73M. 3D Investment Partners Pte. Ltd. was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +252.4% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +252.4% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does MediciNova, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about MNOV's management, answered from reported figures.
Who manages MNOV?
MediciNova, Inc. (MNOV) lists 4 active executives. The top listed executive is David H. Crean, Chief Business Officer.
Are MNOV insiders buying or selling?
Recent insider activity shows net buying of $49.15M.
Continue the stock analysis
Jump to another research area for this company.